O’Sullivan and colleagues conducted a meta-analysis on five randomized trials to compare the efficacy of adjuvant therapy with or without Trastuzumab in patients with HER2+ breast cancer with tumor size ≤2 cm; they showed that the patients derived a substantial DFS and OS benefit from adjuvant Trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.